Corundum Systems Biology

Holobiome is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company focuses on developing microbiome-based therapeutics aimed at addressing diseases of the enteric and central nervous systems. Holobiome's innovative approach involves mapping and manipulating the gut-brain axis through next-generation probiotics, enabling the treatment of mental health disorders such as depression and anxiety, as well as enhancing metabolic and immune responses. By leveraging insights into the human gut microbiome, Holobiome seeks to provide effective therapies that allow patients to recover from their conditions with minimal discomfort.

Freya Biosciences is a clinical-stage women's health company headquartered in Copenhagen and Boston, specializing in the development of microbial immunotherapies. The company focuses on addressing significant unmet medical needs across various indications by utilizing a proprietary platform to engineer and manufacture live microbes. These engineered microbes are designed to be both safe and effective for human use, facilitating the creation of innovative treatments for a range of diseases.

Sequential Skin is a diagnostic platform focused on skin longevity and aging, leveraging expertise in genetics, epigenetics, and the skin microbiome. The company specializes in clinical microbiome testing for skin, scalp, and female health. Its primary offering is a skin health test that employs quantitative real-time PCR (qPCR) technology to analyze specific markers within the skin microbiome. This analysis provides individuals with a detailed understanding of their skin profile, helping them identify their unique skincare needs. By delivering personalized insights, Sequential Skin empowers individuals to make informed decisions about their skincare routines.

Holobiome is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company focuses on developing microbiome-based therapeutics aimed at addressing diseases of the enteric and central nervous systems. Holobiome's innovative approach involves mapping and manipulating the gut-brain axis through next-generation probiotics, enabling the treatment of mental health disorders such as depression and anxiety, as well as enhancing metabolic and immune responses. By leveraging insights into the human gut microbiome, Holobiome seeks to provide effective therapies that allow patients to recover from their conditions with minimal discomfort.

Axial Biotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for central nervous system (CNS) diseases and disorders. Utilizing a microbiome discovery platform, the company targets the gut-brain axis to create innovative therapies aimed at improving the quality of life for patients suffering from neurological conditions. Founded in 2013 and headquartered in Waltham, Massachusetts, Axial Biotherapeutics is in the clinical stage of its development, working to advance its pipeline of novel CNS therapeutics.